CO2021015265A2 - Composiciones y métodos de oximetazolina para el tratamiento de trastornos oculares - Google Patents

Composiciones y métodos de oximetazolina para el tratamiento de trastornos oculares

Info

Publication number
CO2021015265A2
CO2021015265A2 CONC2021/0015265A CO2021015265A CO2021015265A2 CO 2021015265 A2 CO2021015265 A2 CO 2021015265A2 CO 2021015265 A CO2021015265 A CO 2021015265A CO 2021015265 A2 CO2021015265 A2 CO 2021015265A2
Authority
CO
Colombia
Prior art keywords
oxymetazoline
compositions
methods
treatment
ocular disorders
Prior art date
Application number
CONC2021/0015265A
Other languages
English (en)
Inventor
Tina Devries
David Jacobs
Original Assignee
Rvl Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rvl Pharmaceuticals Inc filed Critical Rvl Pharmaceuticals Inc
Publication of CO2021015265A2 publication Critical patent/CO2021015265A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
    • A61J1/10—Bag-type containers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente divulgación está dirigida a composiciones que comprenden oximetazolina y métodos para estabilizar composiciones de oximetazolina para almacenamiento a largo plazo. La presente divulgación también está dirigida a composiciones que comprenden oximetazolina y métodos para tratar diversos trastornos oculares relacionados con párpados caídos, tales como ptosis, en un sujeto que comprende administrar al sujeto composiciones que comprenden oximetazolina.
CONC2021/0015265A 2019-05-06 2021-11-11 Composiciones y métodos de oximetazolina para el tratamiento de trastornos oculares CO2021015265A2 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962844069P 2019-05-06 2019-05-06
US201962843819P 2019-05-06 2019-05-06
US16/715,998 US10814001B1 (en) 2019-05-06 2019-12-16 Oxymetazoline compositions
US16/716,014 US10799481B1 (en) 2019-05-06 2019-12-16 Compositions and methods for treating ocular disorders
PCT/US2020/031425 WO2020227260A1 (en) 2019-05-06 2020-05-05 Oxymetazoline compositions and methods for treating ocular disorders

Publications (1)

Publication Number Publication Date
CO2021015265A2 true CO2021015265A2 (es) 2022-02-28

Family

ID=72750169

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0015265A CO2021015265A2 (es) 2019-05-06 2021-11-11 Composiciones y métodos de oximetazolina para el tratamiento de trastornos oculares

Country Status (17)

Country Link
US (11) US10799481B1 (es)
EP (1) EP3965737A1 (es)
JP (2) JP7141420B2 (es)
KR (1) KR102410503B1 (es)
CN (2) CN117045596A (es)
AU (1) AU2020268329A1 (es)
BR (1) BR112021022404A2 (es)
CA (1) CA3139443A1 (es)
CL (1) CL2021002918A1 (es)
CO (1) CO2021015265A2 (es)
IL (1) IL287831A (es)
MA (1) MA55895A (es)
MX (1) MX2021013516A (es)
PE (1) PE20220384A1 (es)
SG (1) SG11202112272TA (es)
WO (1) WO2020227260A1 (es)
ZA (1) ZA202108950B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120225918A1 (en) * 2011-03-03 2012-09-06 Voom, Llc Compositions and Methods for Non-Surgical Treatment of Ptosis
WO2022187306A1 (en) 2021-03-03 2022-09-09 Voom, Llc Compositions and methods for treatment of blepharitis
WO2023079427A1 (en) * 2021-11-03 2023-05-11 Avaca Pharma Private Limited Ophthalmic compositions and methods thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE51421B1 (en) 1980-08-01 1986-12-24 Smith & Nephew Ass Ophthalmic compositions containing triamterene
US5459133A (en) 1992-06-05 1995-10-17 Telor Ophthalmic Pharmaceuticals, Inc. Methods and products for treating presbyopia
US5888493A (en) 1996-12-05 1999-03-30 Sawaya; Assad S. Ophthalmic aqueous gel formulation and related methods
DE10337186A1 (de) * 2003-08-13 2005-03-17 Merck Patent Gmbh Wässrige Wirkstoff-Lösung
US7812049B2 (en) 2004-01-22 2010-10-12 Vicept Therapeutics, Inc. Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
JP2006131628A (ja) * 2004-10-08 2006-05-25 Rohto Pharmaceut Co Ltd オキシメタゾリン含有水性組成物
US8758816B2 (en) 2004-11-24 2014-06-24 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
CA2646424C (en) 2006-03-17 2015-12-29 Johnson & Johnson Vision Care, Inc. Methods for stabilizing oxidatively unstable compositions
JP2009535342A (ja) 2006-04-26 2009-10-01 アーシエックス， インコーポレイテッド 眼瞼腫脹の予防および処置のための組成物
US8466203B2 (en) * 2006-12-06 2013-06-18 David Choohyun Paik Method of stabilizing human eye tissue by reaction with nitrite and related agents such as nitro compounds
CN101951886A (zh) * 2007-12-21 2011-01-19 先灵-普劳健康护理产品公司 增强羟甲唑啉的光稳定性
MX2010009974A (es) * 2008-03-11 2010-09-30 Alcon Res Ltd Suspensiones de acetonida de triamcinolona de baja viscosidad, altamente floculadas para inyeccion intravitrea.
CA2764477A1 (en) * 2009-06-05 2010-12-09 Aciex Therapeutics, Inc. Ophthalmic formulations, methods of manufacture, and methods of using same
US20120082625A1 (en) 2010-09-28 2012-04-05 Michael Graeber Combination treatment for rosacea
CA2812164A1 (en) * 2010-11-08 2012-05-18 Healor Ltd. Buffered ophthalmic compositions and methods of use thereof
EP2645993B1 (en) 2010-12-03 2016-11-02 Allergan, Inc. Pharmaceutical cream compositions comprising oxymetazoline
US20120225918A1 (en) * 2011-03-03 2012-09-06 Voom, Llc Compositions and Methods for Non-Surgical Treatment of Ptosis
JP2015518006A (ja) 2012-05-25 2015-06-25 エクスクリア インコーポレイテッド キシリトール系の抗粘膜組成物及び関連する方法並びに組成物
UA119324C2 (uk) 2013-04-02 2019-06-10 Теміс Медікер Лімітед Композиції фармацевтично активних речовин, що містять моноетиловий ефір діетиленгліколю або інші алкільні похідні
CN106063399B (zh) 2013-09-18 2019-03-15 迈康尼股份公司 用于处理smt系统中的托盘的方法、系统和装置
ES2796871T3 (es) 2014-06-11 2020-11-30 Epi Health Llc Formulaciones de oximetazolina estabilizadas y sus usos
EP3302426A4 (en) 2015-05-29 2018-12-05 Sydnexis, Inc. D2o stabilized pharmaceutical formulations
US20170312335A1 (en) * 2015-12-30 2017-11-02 Lubris Llc Topical use of prg4 for treatment of allergy and symptoms of inflammation
AU2017211793B2 (en) 2016-01-26 2022-11-24 Levation Pharma Ltd. Compositions and uses of alpha-adrenergic agents
CN105997856A (zh) * 2016-06-24 2016-10-12 魏威 盐酸羟甲唑啉滴眼液及其制备方法
US11246816B2 (en) 2016-06-30 2022-02-15 The Procter And Gamble Company Shampoo compositions comprising a chelant

Also Published As

Publication number Publication date
JP2020183373A (ja) 2020-11-12
US20200353083A1 (en) 2020-11-12
US11103482B2 (en) 2021-08-31
US20210137889A1 (en) 2021-05-13
US10898573B1 (en) 2021-01-26
KR20220084264A (ko) 2022-06-21
US20210212992A1 (en) 2021-07-15
ZA202108950B (en) 2023-10-25
US20230355587A1 (en) 2023-11-09
CN117045596A (zh) 2023-11-14
KR20200128629A (ko) 2020-11-16
US10940138B2 (en) 2021-03-09
BR112021022404A2 (pt) 2022-01-18
CN111888326A (zh) 2020-11-06
US20210023222A1 (en) 2021-01-28
PE20220384A1 (es) 2022-03-18
US20210015795A1 (en) 2021-01-21
EP3965737A1 (en) 2022-03-16
US20220257566A1 (en) 2022-08-18
JP7141420B2 (ja) 2022-09-22
US11701343B2 (en) 2023-07-18
MA55895A (fr) 2022-03-16
US10799481B1 (en) 2020-10-13
US11324722B2 (en) 2022-05-10
SG11202112272TA (en) 2021-12-30
AU2020268329A1 (en) 2022-01-06
CL2021002918A1 (es) 2022-08-19
US20220273621A1 (en) 2022-09-01
US20240033250A1 (en) 2024-02-01
MX2021013516A (es) 2022-01-24
US11541036B2 (en) 2023-01-03
CA3139443A1 (en) 2020-11-12
JP2021191802A (ja) 2021-12-16
US11311515B2 (en) 2022-04-26
US10814001B1 (en) 2020-10-27
US20210386711A1 (en) 2021-12-16
IL287831A (en) 2022-01-01
WO2020227260A1 (en) 2020-11-12
CN111888326B (zh) 2023-07-21
KR102410503B1 (ko) 2022-06-17

Similar Documents

Publication Publication Date Title
CO2021015265A2 (es) Composiciones y métodos de oximetazolina para el tratamiento de trastornos oculares
CL2016002812A1 (es) Uso de ácido 3-2,3,5,6-tetrafluoro-3-trifluorometoxi-bifenil-4-ilcarbamoil-tiofeno-2-carboxílico para preparar un medicamento útil para tratar una enfermedad ocular que es uveítis, ojo seco o causada por un adenovirus composición formulación.
AR120961A2 (es) Método y composición para tratar hipertensión ocular y glaucoma
TW201613588A (en) Ophthalmic composition
BR112017024531A2 (pt) lentes intraoculares ajustáveis por luz usando nanopartículas de conversão ascendente e luz do infravermelho próximo (nir)
WO2016172712A3 (en) Ophthalmic composition
EA201890641A2 (ru) СТИМУЛЯТОРЫ sGC
CO2021006075A2 (es) Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad de nlrp
ECSP16072941A (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
CL2020002734A1 (es) Tratamientos para la presbicia
AR097209A1 (es) Guía quirúrgica y software de planificación para el tratamiento del astigmatismo
MX2020005217A (es) Composicion oftalmica y dispositivo de administracion de la misma.
CO2017001454A2 (es) Composiciones en suspensión de ciclosporina a para inyecciones subconjuntivales y perioculares
IN2014CN02153A (es)
BR112014010376A2 (pt) medicamento para o tratamento de doença do olho anterior que compreende rebamipida e um agente de retenção de lágrima
CL2017001301A1 (es) Composiciones oftálmicas estabilizadas de omega 3
BR112015022577A2 (pt) moduladores ship1 e métodos relacionados a esse
BR112017020132A2 (pt) métodos para promover o crescimento capilar ou prevenir a perda de cabelo em um indivíduo e para preparar uma composição, e, composição
MX2016012933A (es) Composiciones de relleno de tejidos y metodos de uso.
BR112019000504A2 (pt) métodos e composições poliméricas para o tratamento de descolamento de retina e outros distúrbios oculares
MX2016015211A (es) Formulaciones topicas y usos de las mismas.
EA201990752A1 (ru) Офтальмологический состав, содержащий цитиколин, переносимый липосомой, для лечения глаукомы
EA201591626A1 (ru) Искусственные факторы транскрипции для лечения заболеваний, вызываемых гаплонедостаточностью opa1
CL2019001338A1 (es) Preparación cosmética de viscosidad mejorada para el tratamiento de las fibras queratínicas, proceso para el aumento de la viscosidad de una preparación cosmética, uso de ingredientes modificadores de la viscosidad y método de tratamiento de las fibras queratínicas.
AR110947A1 (es) Tratamiento de degeneración de la retina mediante el uso de células progenitoras